These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34962399)

  • 21. In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa.
    Wong PC; Quan ML; Watson CA; Crain EJ; Harpel MR; Rendina AR; Luettgen JM; Wexler RR; Schumacher WA; Seiffert DA
    J Thromb Thrombolysis; 2015 Nov; 40(4):416-23. PubMed ID: 26249722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
    Corte JR; Fang T; Osuna H; Pinto DJ; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Decicco CP; Wexler RR; Quan ML
    J Med Chem; 2017 Feb; 60(3):1060-1075. PubMed ID: 28085275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
    Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
    J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrocyclic factor XIa inhibitors.
    Wang C; Corte JR; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4056-4060. PubMed ID: 28780160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors.
    Argade MD; Mehta AY; Sarkar A; Desai UR
    J Med Chem; 2014 Apr; 57(8):3559-69. PubMed ID: 24666186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyridine and pyridinone-based factor XIa inhibitors.
    Corte JR; Fang T; Hangeland JJ; Friends TJ; Rendina AR; Luettgen JM; Bozarth JM; Barbera FA; Rossi KA; Wei A; Ramamurthy V; Morin PE; Seiffert DA; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2015 Feb; 25(4):925-30. PubMed ID: 25592713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying new clotting factor XIa inhibitors in virtual high-throughput screens using PCA-GA-SVM models and signature.
    Chen JJ; Schmucker LN; Visco DP
    Biotechnol Prog; 2018 Nov; 34(6):1553-1565. PubMed ID: 30009405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commentary on "Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa": Small molecule factor XIa inhibitor asundexian allows for safer anticoagulation.
    Mailer RK; Renné T
    J Thromb Haemost; 2022 Jun; 20(6):1309-1311. PubMed ID: 35596514
    [No Abstract]   [Full Text] [Related]  

  • 29. Recent advances in the discovery and development of factor XI/XIa inhibitors.
    Al-Horani RA; Afosah DK
    Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine.
    Deng H; Bannister TD; Jin L; Babine RE; Quinn J; Nagafuji P; Celatka CA; Lin J; Lazarova TI; Rynkiewicz MJ; Bibbins F; Pandey P; Gorga J; Meyers HV; Abdel-Meguid SS; Strickler JE
    Bioorg Med Chem Lett; 2006 Jun; 16(11):3049-54. PubMed ID: 16524727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.
    Pinto DJ; Galemmo RA; Quan ML; Orwat MJ; Clark C; Li R; Wells B; Woerner F; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; He K; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5584-9. PubMed ID: 16963264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
    Pinto DJP; Orwat MJ; Smith LM; Quan ML; Lam PYS; Rossi KA; Apedo A; Bozarth JM; Wu Y; Zheng JJ; Xin B; Toussaint N; Stetsko P; Gudmundsson O; Maxwell B; Crain EJ; Wong PC; Lou Z; Harper TW; Chacko SA; Myers JE; Sheriff S; Zhang H; Hou X; Mathur A; Seiffert DA; Wexler RR; Luettgen JM; Ewing WR
    J Med Chem; 2017 Dec; 60(23):9703-9723. PubMed ID: 29077405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists.
    Porter DW; Bradley M; Brown Z; Charlton SJ; Cox B; Hunt P; Janus D; Lewis S; Oakley P; O'Connor D; Reilly J; Smith N; Press NJ
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3285-90. PubMed ID: 24974342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
    Sunose M; Bell K; Ellard K; Bergamini G; Neubauer G; Werner T; Ramsden N
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4613-8. PubMed ID: 22726925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.
    Siu M; Pastor R; Liu W; Barrett K; Berry M; Blair WS; Chang C; Chen JZ; Eigenbrot C; Ghilardi N; Gibbons P; He H; Hurley CA; Kenny JR; Cyrus Khojasteh S; Le H; Lee L; Lyssikatos JP; Magnuson S; Pulk R; Tsui V; Ultsch M; Xiao Y; Zhu BY; Sampath D
    Bioorg Med Chem Lett; 2013 Sep; 23(17):5014-21. PubMed ID: 23870430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of the Triazolo[1,5-
    Wang S; Wang SQ; Teng QX; Lei ZN; Chen ZS; Chen XB; Liu HM; Yu B
    J Med Chem; 2021 Nov; 64(21):16187-16204. PubMed ID: 34723530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
    Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2.
    Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Higgins GA; Cohen-Williams ME; Varty GB; Tulshian DB
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3675-8. PubMed ID: 15982882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa.
    Hanessian S; Larsson A; Fex T; Knecht W; Blomberg N
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6925-8. PubMed ID: 21035339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful medical treatment of a case of Paecilomyces lilacinus keratitis.
    Ford JG; Agee S; Greenhaw ST
    Cornea; 2008 Oct; 27(9):1077-9. PubMed ID: 18812777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.